Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

Heppner, DE; Wittlinger, F; Beyett, TS; Shaurova, T; Urul, DA; Buckley, B; Pham, CD; Schaeffner, IK; Yang, B; Ogboo, BC; May, EW; Schaefer, EM; Eck, MJ; Laufer, SA; Hershberger, PA

Heppner, DE (通讯作者)，Univ Buffalo, State Univ New York, Dept Chem, Buffalo, NY 14260 USA.;Heppner, DE (通讯作者)，Roswell Pk Comprehens Canc Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14203 USA.

ACS MEDICINAL CHEMISTRY LETTERS, 2022; 13 (12): 1856

Abstract

Lazertinib (YH25448) is a novel third-generation tyrosine kinase inhibitor (TKI) developed as a treatment for EGFR mutant non-small cell lung cancer. ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索